Active Clinical Trials

Numerous clinical trials are always active (i.e., open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. This section of the website contains a searchable list of all active trials. On the table below, hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword. To access more information about a particular trial, click on the trial ID.



Cancer TypeTrial ID/More InfoTarget Patient PopulationStudy TypeECOG-ACRIN Oversight Committee(s)
VariousEAY191 / ComboMATCHPatients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (advanced)Patient RegistrationDevelopmental Therapeutics
VariousEAY191-E4

Metastatic (advanced) solid tumors that are progressing after treatment with taxane chemotherapy

TreatmentDevelopmental Therapeutics
AnyEAQ202Ages 18-39 with any type of cancer except basal cell carcinomaObservation (Patient Reporting) Cancer Control and Survivorship Committee and its Patient-Reported Outcomes Working Group; Health Equity Committee and its Adolescent and Young Adult Oncology Subcommittee
AnyEAQ172Cancer patients with pneumonitis (lung inflammation)Treatment Cancer Control and Survivorship
AnusEA2176Metastatic (advanced), not able to be removed by surgery (inoperable)TreatmentGastrointestinal
AnusEA2182 / DECREASESquamous cell type, no prior treatmentTreatmentGastrointestinal
BladderEA8185 / INSPIREHas spread to the lymph nodesTreatmentGenitourinary
BladderEA8212 / BRIDGEHigh risk; has not spread to the muscleย TreatmentGenitourinary
BloodEA9152 Acute lymphoblastic leukemia (ALL)TreatmentLeukemia
BloodEA9181Acute lymphoblastic leukemia (ALL) TreatmentLeukemia
BloodEA9213Acute lymphoblastic leukemia (ALL), T-cell TypeTreatmentLeukemia
BloodEA9171 / BLAST MRD CML 1Chronic myelogenous leukemia (CML)TreatmentLeukemia
BloodE4412 Hodgkin lymphomaTreatmentLymphoma
BloodEA4151 Mantle cell lymphomaTreatmentLymphoma
BloodEAA181 / EQUATEMyeloma, newly diagnosed Treatment Myeloma
BloodEAA173 / DETER-SMMSmoldering myeloma TreatmentMyeloma
BloodPrE0905Acute myeloid leukemia with FLT3 mutationTreatmentN/A (PrECOG)
BloodNHLBI-MDS / The National MDS StudySuspected myelodysplastic syndromesScreening/Early DetectionLeukemia
BrainEAF151Recurrent glioblastomaTreatmentBrain Cancer Working Group
BreastEA1151 / TMISTWomen planning for regular mammogramsScreening/Early DetectionImaging; Prevention; Breast
BreastEA1181 / CompassHER2 pCRHER2 positive typeTreatmentBreast
BreastEA1183 / FEATUREMetastatic (advanced) with bone or mostly bone diseaseImagingBreast
BreastEA1211 / DIRECTHER-2 positive, early stageTreatmentBreast
EsophagusEA2174Locally advanced, able to be removed by surgery (operable)TreatmentGastrointestinal
Esophagus and StomachEA2183Metastatic (advanced), HER2 negative typeTreatmentGastrointestinal
GallbladderEA2197 / OPT-INDiscovered at time of surgery to remove the gallbladderTreatmentGastrointestinal
Head and NeckEA3132p53-mutated squamous cell type, after surgeryTreatmentHead and Neck
Head and NeckEA3191Squamous cell carcinoma of the head and neck that has come back after initial therapyTreatmentHead and Neck
Head and NeckEA3202Metastatic (advanced) squamous cell type that has returned after treatment with immune checkpoint inhibitorsTreatment Head and Neck
Kidney or ThyroidEAQ191 / CARISMABlood pressure managementTreatmentCancer Control and Survivorship
LiverEA2205Metastatic (advanced) or not able to be removed by surgery (inoperable)TreatmentGastrointestinal
LungEA5162 Non-small cell type, metastatic (advanced)TreatmentThoracic
LungEA5163 / S1709 / INSIGNANon-small cell type, metastatic (advanced)TreatmentThoracic
LungEA5181Non-small cell type, not able to be removed by surgery (inoperable)TreatmentThoracic
LungEA5182 Non-small cell type, metastatic (advanced)TreatmentThoracic
LungEA5191 Non-small cell, non-squamous typeTreatmentThoracic
LungE4512, an ALCHEMIST TrialNon-small cell type, able to be removed by surgery (operable)TreatmentThoracic
Melanoma (Skin)EA6141Metastatic (advanced)TreatmentMelanoma
Melanoma (Skin) EA6174 / STAMPMerkel cell type TreatmentMelanoma
Melanoma (Skin)EA6192 / PET-StopMetastatic (advanced)TreatmentMelanoma
Melanoma (Skin)EA6194Able to be removed by surgery (operable)TreatmentMelanoma
MesotheliomaPrE0506 / DREAM3R6Advanced pleuralTreatmentN/A (PrECOG)
Nose and SinusEA3163Squamous cell type, able to be removed by surgeryTreatmentHead and Neck
PancreasEA2185Patients with non-cancerous pancreas cystsScreening/Early DetectionGastrointestinal
PancreasEA2186 / GIANTMetastatic (advanced), older (aged 70+)TreatmentGastrointestinal; Geriatric Oncology Working Group
PancreasEA2192 / APOLLOHas been surgically removed and has a BRCA1, BRCA2, or PALB2 mutationTreatmentGastrointestinal
PenisEA8134 / InPACTMetastatic (advanced)TreatmentGenitourinary
ProstateEA8171Newly diagnosed, before surgeryImaging/Treatment PlanningGenitourinary
ProstateEA8184On close monitoring; at low risk of progressingPreventionGenitourinary
ProstateEA8191 / INDICATEHas come back after surgeryTreatmentGenitourinary
RectumEA2201Locally advanced, MSI-H or dMMR typeTreatmentGastrointestinal
ThroatEA3161HPV positive typeTreatmentHead and Neck
Upper Urinary TractEA8192High grade (aggressive)TreatmentGenitourinary
ECOG-ACRIN Cancer Research Group